STAT+: Three biotechs with three news updates

STAT PlusNewsletterThe Readout Three biotechs with three news updates Gilead wins case over its HIV medicine, Eli Lilly to expand retatrutide access, and more biotech news Manage alerts for this article Email this article Share this article By Elaine ChenAug. 4, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. I’ve decided to paint the walls in one of my rooms a dark brown. I may deeply regret this decision.

Please send any painting tips!Advertisement The need-to-know this morning Earnings: Vertex, Pfizer, and Merck. Lilly will review applications for special access to experimental drug Over a month ago, STAT reported that Eli Lilly had granted a single 79-year-old patient special access to its next-gen obesity drug retatrutide. Now, the pharma company says it will allow other patients to apply for early access to the therapy as well.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account?

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.

Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Exclusive August 3, 2026 STAT Plus: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug The Readout August 3, 2026 STAT Plus: Is there a pharma mega-merger in the making? Advertisement Biotech August 3, 2026 STAT Plus: BioNTech names Guido Oelkers its new CEO First Opinion July 31, 2026 Limb girdle muscular dystrophy patients face a maddening reality Biotech July 30, 2026 STAT Plus: FDA expert committee votes in favor of Replimune’s melanoma treatment Subscriber Picks